Spero Therapeutics, Inc. entered into an Open Market Sale Agreement with Jefferies LLC on August 28, 2026, establishing a new at-the-market equity offering program allowing the sale of up to $100 million in common stock. Concurrently, the company terminated its prior Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co., which had authorized up to $75 million in sales but resulted in zero shares sold through that channel. Jefferies will act as sales agent for a commission of up to 3.0% of gross proceeds. Spero Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on the development and commercialization of treatments for infectious diseases.

Spero Therapeutics reported a net loss of $9.6 million for Q2 2026, compared to $1.7 million in the prior year period, with no revenue recognized as deferred amounts were fully recognized previously. The company secured $105 million in non-recourse royalty financing backed by future Utebzi proceeds from GSK, extending its cash runway into late 2029. Spero also entered an exclusive license agreement for SP001 with Innovent Biologics and appointed Debra Zack as Chief Medical Officer. Additionally, the FDA approved Utebzi for complicated urinary tract infections. Spero Therapeutics is a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation.

Spero Therapeutics, Inc. entered into a license agreement with Innovent Biologics to develop and commercialize a CD40L monoclonal antibody, involving a $35.0 million upfront payment and up to $1.05 billion in milestone payments. Additionally, the company secured royalty financing through a $105.0 million senior secured note purchase and a royalty interest purchase, which is expected to extend its cash runway into the second half of 2029. Spero Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions for infectious diseases and inflammatory conditions.

At its Annual Meeting on June 23, 2026, Spero Therapeutics stockholders approved an amendment to the Amended and Restated Certificate of Incorporation to increase the total number of authorized shares of common stock from 120,000,000 to 240,000,000. Stockholders also approved the 2026 Stock Incentive Plan, which allows for the issuance of up to 12,895,866 shares of common stock. The company operates in the biotechnology industry and develops therapies for infectious diseases.

Spero Therapeutics, Inc. announced that the FDA has granted approval for Utebzi (tebipenem pivoxil), the first and only oral carbapenem antibiotic approved for treating complicated urinary tract infections (cUTIs), including pyelonephritis, in adult patients with limited or no alternative oral treatment options. The approval was received ahead of the PDUFA date of June 18, 2026. Spero Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing antibiotic treatments.